SG11201811788SA - Antibodies with low immunogenicity and uses thereof - Google Patents

Antibodies with low immunogenicity and uses thereof

Info

Publication number
SG11201811788SA
SG11201811788SA SG11201811788SA SG11201811788SA SG11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA SG 11201811788S A SG11201811788S A SG 11201811788SA
Authority
SG
Singapore
Prior art keywords
antibodies
international
pct
san diego
binding
Prior art date
Application number
SG11201811788SA
Other languages
English (en)
Inventor
Jeffrey Johnson
Lawrence Dearth
Haralambos Hadjivassiliou
Jeonghoon Sun
Kandasamy Hariharan
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of SG11201811788SA publication Critical patent/SG11201811788SA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
SG11201811788SA 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof SG11201811788SA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662359150P 2016-07-06 2016-07-06
PCT/US2017/040653 WO2018009499A1 (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Publications (1)

Publication Number Publication Date
SG11201811788SA true SG11201811788SA (en) 2019-01-30

Family

ID=60913146

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201811788SA SG11201811788SA (en) 2016-07-06 2017-07-05 Antibodies with low immunogenicity and uses thereof

Country Status (19)

Country Link
US (1) US11427632B2 (ru)
EP (1) EP3481862A4 (ru)
JP (1) JP7120989B2 (ru)
KR (1) KR20190035737A (ru)
CN (1) CN109689684B (ru)
AR (1) AR108975A1 (ru)
AU (1) AU2017292752B2 (ru)
BR (1) BR112019000166A2 (ru)
CA (1) CA3029977A1 (ru)
CL (1) CL2019000019A1 (ru)
CO (1) CO2019001112A2 (ru)
EA (1) EA201990218A1 (ru)
EC (1) ECSP19008417A (ru)
IL (1) IL264009A (ru)
MX (1) MX2019000172A (ru)
SG (1) SG11201811788SA (ru)
TW (1) TW201811824A (ru)
WO (1) WO2018009499A1 (ru)
ZA (1) ZA201900070B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11401329B2 (en) 2017-08-02 2022-08-02 Phanes Therapeutics, Inc. Anti-CD47 antibodies and uses thereof
KR102115300B1 (ko) * 2018-06-01 2020-05-26 재단법인 목암생명과학연구소 항체 라이브러리 및 이를 이용한 항체 스크리닝 방법
TW202045550A (zh) * 2019-04-05 2020-12-16 美商西建公司 腫瘤選擇性結合cd47之抗體之工程
JP2022535286A (ja) 2019-06-07 2022-08-05 エーエルエックス オンコロジー インコーポレイテッド 血清学的アッセイにおいてｃｄ４７に結合する薬物の干渉を低減するための方法及び試薬
CN116685348A (zh) 2020-10-07 2023-09-01 细胞基因公司 淋巴恶性肿瘤病状的双特异性抗体治疗
EP4256336A1 (en) 2020-12-06 2023-10-11 ALX Oncology Inc. Multimers for reducing the interference of drugs that bind cd47 in serological assays

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE151110T1 (de) 1988-09-02 1997-04-15 Protein Eng Corp Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen
WO1991010737A1 (en) 1990-01-11 1991-07-25 Molecular Affinities Corporation Production of antibodies using gene libraries
GB9026912D0 (en) 1990-12-11 1991-01-30 Wessex Instrumentation Limited Reaction detection equipment
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
EP0590067A1 (en) 1991-06-14 1994-04-06 Xoma Corporation Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
ATE275198T1 (de) 1991-12-02 2004-09-15 Medical Res Council Herstellung von antikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken.
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7321026B2 (en) 2001-06-27 2008-01-22 Skytech Technology Limited Framework-patched immunoglobulins
EP1539233B1 (en) 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
KR20120035234A (ko) * 2003-04-11 2012-04-13 메디뮨 엘엘씨 재조합 ｉｌ?９ 항체 및 그의 용도
US20060228350A1 (en) 2003-08-18 2006-10-12 Medimmune, Inc. Framework-shuffling of antibodies
BRPI0415457A (pt) 2003-10-16 2006-12-05 Micromet Ag constructo de ligação especìfico de cd3 citotoxicamente ativo, seu processo de produção, composição compreendendo o mesmo, seqüência de ácido nucléico, vetor, hospedeiro, seus usos na preparação de uma composição farmacêutica e kit compreendendo os mesmo
US7354854B2 (en) 2005-05-24 2008-04-08 Texas Instruments Incorporated Nickel silicide method and structure
NZ563213A (en) 2005-06-01 2009-07-31 Micromet Ag Anti-IL2 antibodies
BRPI0709917A2 (pt) 2006-03-30 2011-07-05 Novartis Ag composições e métodos de uso para anticorpos de c-met
CA2673725C (en) * 2006-12-20 2016-01-12 Mmr Information Systems, Inc. Antibodies and methods for making and using them
EP2014681A1 (en) * 2007-07-12 2009-01-14 Pierre Fabre Medicament Novel antibodies inhibiting c-met dimerization, and uses thereof
CA2777527C (en) 2009-12-23 2020-06-23 Esbatech, An Alcon Biomedical Research Unit Llc Method for decreasing immunogenicity
EP2536764B1 (en) 2010-02-18 2018-07-04 OSE Immunotherapeutics Anti-cd28 humanized antibodies
PT2812443T (pt) * 2012-02-06 2019-09-05 Inhibrx Inc Anticorpos cd47 e métodos de utilização dos mesmos
EP3505534A1 (en) 2012-06-08 2019-07-03 Sutro Biopharma, Inc. Antibodies comprising sitespecific nonnatural amino acid residues, methods of their preparation and methods of their use
BR112015004022B1 (pt) 2012-08-31 2023-04-25 Sutro Biopharma, Inc Aminoácidos modificados compreendendo um grupo azido
EP4137518A1 (en) 2013-02-06 2023-02-22 Inhibrx, Inc. Non-platelet depleting and non-red blood cell depleting cd47 antibodies and methods of use thereof
WO2016073879A2 (en) 2014-11-06 2016-05-12 Scholar Rock, Inc. Transforming growth factor-related antibodies and uses thereof
EA201791093A1 (ru) 2014-11-18 2018-04-30 Янссен Фармацевтика Нв Антитела к cd47, способы и применение
BR112017014258A2 (pt) * 2014-12-30 2018-03-06 Celgene Corp anticorpos anti-cd47 e usos dos mesmos
JP2018535692A (ja) * 2015-09-21 2018-12-06 エラスムス ユニバーシティ メディカル センターＥｒａｓｍｕｓ Ｕｎｉｖｅｒｓｉｔｙ Ｍｅｄｉｃａｌ Ｃｅｎｔｅｒ 抗ｃｄ４７抗体及び使用方法

Also Published As

Publication number Publication date
CO2019001112A2 (es) 2019-02-19
AR108975A1 (es) 2018-10-17
US11427632B2 (en) 2022-08-30
MX2019000172A (es) 2019-09-26
WO2018009499A1 (en) 2018-01-11
CL2019000019A1 (es) 2019-06-28
CA3029977A1 (en) 2018-01-11
CN109689684A (zh) 2019-04-26
TW201811824A (zh) 2018-04-01
ECSP19008417A (es) 2019-02-28
JP7120989B2 (ja) 2022-08-17
KR20190035737A (ko) 2019-04-03
BR112019000166A2 (pt) 2019-10-01
CN109689684B (zh) 2022-09-23
AU2017292752A1 (en) 2019-01-24
JP2019524087A (ja) 2019-09-05
AU2017292752B2 (en) 2023-07-27
EP3481862A1 (en) 2019-05-15
IL264009A (en) 2019-01-31
US20190241654A1 (en) 2019-08-08
EP3481862A4 (en) 2020-08-12
EA201990218A1 (ru) 2019-07-31
ZA201900070B (en) 2023-08-30

Similar Documents

Publication Publication Date Title
SG11201811788SA (en) Antibodies with low immunogenicity and uses thereof
SG11201807252QA (en) Anti-lag-3 antibodies
SG11201804915RA (en) Methods for treating huntington's disease
SG11201900269XA (en) Channel sensing for independent links
SG11201908971RA (en) Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene
SG11201811602QA (en) Extreme ultraviolet mask blank with alloy absorber and method of manufacture
SG11201809879WA (en) Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201903857UA (en) Antibodies to pd-1 and uses thereof
SG11201811396XA (en) Extreme ultraviolet mask blank with multilayer absorber and method of manufacture
SG11201901959YA (en) Modified stem cell memory t cells, methods of making and methods of using same
SG11201903830TA (en) Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies
SG11201901307VA (en) Heterodimeric immunoglobulin constructs and preparation methods thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201809857TA (en) Anti-CTLA-4 Antibodies
SG11201807794VA (en) Naphthene-containing distillate stream compositions and uses thereof
SG11201809645VA (en) Peer-to-peer network and node of a peer-to-peer network
SG11201908678XA (en) Methods and compositions for reduction of immunogenicity
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201811765TA (en) Methods and systems for providing transportation service
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201903785TA (en) Bivalent antibodies masked by coiled coils
SG11201805001UA (en) Method of treating influenza a
SG11201809830WA (en) Selective reduction of cysteine-engineered antibodies
SG11201907948TA (en) Formulations comprising pd-1 binding proteins and methods of making thereof
SG11201807596YA (en) Gitr antibodies, methods, and uses